Want to see RAPP full AI Analyst Report?
Top Page
Rapport Therapeutics, Inc.
(NASDAQ:RAPP)
Select Model
Select Model
Rating:53Neutral
Price Target:
$50.00
▲(22.91% Upside)
Action:Reiterated
Date:08/05/26
The score is primarily constrained by weak financial performance—large operating losses and significant cash burn despite early revenue and strong gross margins. Technicals are a secondary positive with an improving trend and neutral momentum, while valuation remains challenged due to negative earnings and no dividend. Corporate events add a small governance-stability positive but do not materially change the risk profile.
Positive Factors
Pipeline Advancement
Progress into Phase 3 and enrollment across seizure studies increase the pipeline’s potential commercial value. Additional bipolar mania, injectable, and generalized seizure programs provide indication diversification and multiple future development milestones.
Negative Factors
Deep Operating Losses
The company remains far from profitability despite emerging revenue, as heavy R&D and operating expenses drive losses. Sustained negative earnings limit internal funding capacity and make successful clinical and commercial execution essential to long-term value creation.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline Advancement
Progress into Phase 3 and enrollment across seizure studies increase the pipeline’s potential commercial value. Additional bipolar mania, injectable, and generalized seizure programs provide indication diversification and multiple future development milestones.
Read all positive factors
Rapport Therapeutics, Inc. (RAPP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.35B
Dividend YieldN/A
Average Volume (3M)404.29K
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue GrowthN/A
EPS Growth-23.53%
CountryUS
Employees84
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.04
Shares Outstanding47,978,287
10 Day Avg. Volume321,428
30 Day Avg. Volume404,290
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$60.25Price Target Upside48.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$20.00M
Rapport Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorder...
How the Company Makes Money
null...
Rapport Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 20.00M | -1.02M | 0.00 | 0.00 | -15.00K |
| EBITDA | -148.14M | -124.08M | -82.22M | -36.07M | -10.35M |
| Net Income | -137.16M | -111.48M | -78.31M | -34.79M | -10.65M |
Balance Sheet | |||||
| Total Assets | 458.98M | 512.43M | 314.93M | 155.42M | 31.60M |
| Cash, Cash Equivalents and Short-Term Investments | 436.08M | 490.54M | 305.28M | 147.48M | 31.16M |
| Total Debt | 10.11M | 11.48M | 1.48M | 2.15M | 10.44M |
| Total Liabilities | 36.06M | 27.78M | 9.51M | 181.06M | 12.10M |
| Stockholders Equity | 422.93M | 484.65M | 305.43M | -25.63M | 19.50M |
Cash Flow | |||||
| Free Cash Flow | -97.15M | -88.09M | -67.23M | -28.82M | -3.53M |
| Operating Cash Flow | -96.68M | -87.47M | -64.83M | -27.18M | -3.24M |
| Investing Cash Flow | -167.56M | -187.47M | -170.14M | -78.86M | -5.28M |
| Financing Cash Flow | 272.79M | 270.79M | 221.63M | 145.14M | 39.69M |
Rapport Therapeutics, Inc. Risk Analysis
Rapport Therapeutics, Inc. disclosed 87 risk factors in its most recent earnings report. Rapport Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rapport Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.54B | 4.41 | 30.03% | ― | 18.17% | 693.83% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | $2.35B | -16.14 | -29.02% | ― | ― | -23.53% | |
51 Neutral | $4.40B | -36.21 | -18.55% | ― | ― | 16.63% | |
45 Neutral | $149.88M | -1.20 | -53.39% | ― | 329.50% | -114.98% |
* General Sector Average
RAPP
Rapport Therapeutics, Inc.
49.07
34.75
242.67%
INVA
Innoviva
21.48
1.53
7.67%
ELVN
Enliven Therapeutics
59.39
39.73
202.09%
LENZ
LENZ Therapeutics
4.92
-33.62
-87.23%
Rapport Therapeutics, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting
Positive
Jun 10, 2026
On June 10, 2026, Rapport Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, with 47,807,623 common shares outstanding and eligible to vote as of the April 14, 2026 record date. Stockholders considered the election of three Class II ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.